Mehmood Khan

Khan presents a clear and ambitious healthspan vision centered on treating aging as a biological condition, shifting medicine toward prevention, and accelerating therapies through sustained scientific funding. The vision includes actionable mechanisms but lacks a defined timeline, measurable end state, or detailed scientific theory of change.

There is credible evidence of direct scientific authorship, including clinical research involving older adults and a recent aging-brain publication, but the strongest bibliometric evidence appears misattributed to Hassan Khan rather than Mehmood Khan. The remaining evidence does not establish field-defining scientific influence.

The dimension applies because Khan leads a grantmaking and investment foundation, but the supplied evidence identifies no specific investments, donations, catalytic positions, or independently rated investees. Therefore, no credible, human-trial-stage longevity outcome can be attributed to his capital deployment. The academic sources establish aging-related activity, not capital outcomes.

Khan articulates a coherent thesis that geroscience is entering a capital-intensive translational phase poorly served by conventional funding, and that grantmaking and investment should address this gap. This shows strategic framing, but the evidence does not identify specific early or contrarian allocations, demonstrate catalytic decision-making, or establish counterfactual field impact.

Khan is credibly associated with building Hevolution Foundation as a new funding path for geroscience and with convening the Global Healthspan Summit. Independent academic records attest that both the foundation and summit exist, satisfying the field-building independence gate. However, the evidence does not establish the scale, durability, funding outcomes, or Khan's precise personal role strongly enough for a field-defining score.

Khan demonstrates meaningful public conviction by challenging acceptance of aging as inevitable and advocating nontraditional, large-scale funding for geroscience. Leading an organization with up to $1 billion in annual funding makes the institutional bet consequential, but the evidence does not establish personal financial exposure, career sacrifice, sustained action under serious criticism, or self-experimentation.

Khan leads a real foundation focused on mobilizing funding for geroscience and has helped convene a global healthspan summit, giving him credible field-building leverage beyond direct research. However, the evidence does not quantify capital deployed or demonstrate resulting talent recruitment, collaborations, companies, policy changes, or follow-on projects.